Bictegravir Emtricitabine And Tenofovir alafenamide Tablets

Product Description

The combination medication you mentioned consists of three active ingredients:

1. Bictegravir - Bictegravir is an integrase strand transfer inhibitor (INSTI) used in the treatment of HIV/AIDS. It works by blocking the action of integrase, an enzyme necessary for the HIV virus to multiply.

2. Emtricitabine - Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) that inhibits the activity of reverse transcriptase, another enzyme necessary for HIV replication.

3. Tenofovir alafenamide - As mentioned earlier, tenofovir alafenamide (TAF) is a prodrug of tenofovir, which is also an NRTI. TAF is converted into tenofovir in the body and works similarly to emtricitabine to inhibit HIV replication.

This combination medication is commonly prescribed for the treatment of HIV infection in adults and pediatric patients weighing at least 25 kg. The typical dosage for this combination is one tablet containing bictegravir 50 mg, emtricitabine 200 mg, and tenofovir alafenamide 25 mg, taken orally once daily with or without food.

It's crucial to follow your healthcare provider's instructions regarding dosage and administration, and to inform them of any other medications you may be taking to avoid potential drug interactions. Regular monitoring of HIV viral load and kidney function may also be necessary while taking this medication